UnitedHealth Group faces a DOJ investigation for possible Medicare fraud, leading to its worst monthly stock slump and raising regulatory and market concerns in the U.S. health insurance sector.

New analysis shows Inflation Reduction Act provisions will reduce Medicare Part D out-of-pocket costs for specialty drugs etanercept, ustekinumab, and ibrutinib, improving affordability for beneficiaries.

UnitedHealth Group reports higher medical loss ratio and earnings challenges in Medicare Advantage, signaling a strategic shift amid rising care costs and regulatory scrutiny.

Optum is creating AI-driven risk coding to improve Medicare patient assessments, coinciding with DOJ investigations into Medicare Advantage practices by UnitedHealth Group.

The DOJ is investigating UnitedHealth Group for alleged criminal Medicare fraud focused on its Medicare Advantage business, highlighting regulatory and compliance risks for health insurers.

Cutting Medicaid funding shifts costs to Medicare, increasing federal spending and reducing access to care. Learn how Medicaid supports Medicare affordability and prevents costly hospitalizations.

UnitedHealth Group is reportedly under a DOJ criminal investigation for Medicare fraud, adding to existing probes amid leadership and financial outlook shifts.

Analysis of inflation rebate implementation under the Inflation Reduction Act highlights the need to include Medicare Advantage enrollees to maximize drug cost savings and deter pharmaceutical price hikes.

UnitedHealth Group stock falls sharply as CEO changes and 2025 guidance withdrawal increase uncertainty. Analysis of implications for the health insurance market.

UnitedHealth Group raises 2025 medical cost projections and appoints Stephen Hemsley as CEO amid rising patient utilization and financial outlook withdrawal.